CLDN1 mAb has been designed with a silenced effector function to target the stiff ECM of fibrotic tissues and organs and is currently under development for kidney, lung, and liver fibrosis. ALE.F02’s translational data predict robust efficacy and safety across multiple organ fibrosis indications. Topline data from a Phase 1 clinical trial in healthy volunteers were reported in 2023, several other clinical trials are planned to start during 2023.